3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 1267-1273

  Klingler, Werner ^a   Heffron, James J A ^b   Jurkat Rott, Karin ^a   O'Sullivan, Grainne ^b   Alt, Andreas ^a   Schlesinger, Friedrich ^c   Bufler, Johannes ^c   Lehmann Horn, Frank ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA BUNGAROTOXIN; CAFFEINE; CALCIUM ION; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ACIDIFICATION; ARTICLE; CALCIUM TRANSPORT; CELL VACUOLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; ION CURRENT; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; MUSCLE FORCE; MYOTUBE; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; SENSITIVITY ANALYSIS; SKELETAL MUSCLE;

ANIMALS; CALCIUM; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE FIBERS; MUSCLE, SKELETAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RECEPTORS, NICOTINIC; SARCOPLASMIC RETICULUM;

EID: 23944504098     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.086629     Document Type: Article

References (40)

1. Battaglia G and De Souza EB (1989) Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic system. NIDA Res Monogr 94:240-258.
2. Breucking E, Reimnitz P, Schara U, and Mortier W (2000) Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types. Anaesthesist 49:187-195.
3. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, Carvalho F, and Bastos ML (2002) Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 76:581-588.
4. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743.
5. De Letter EA, Bouche LA, Bocxlaer JFV, Lambert WE, and Piette MHA (2004) Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int 141:85-90.
6. Evans M and Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: all statins the same? Drug Saf 25:649-663.
7. Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Menge M, and Schulte Am Esch J (2003) Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy"). Anesthesiology 99:1132-1136.
8. Galloway GJ and Denborough MA (1986) Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 58:447-450.
9. Gattenlohner S, Schneider C, Thamer C, Klein R, Roggendorf W, Gohlke F, Niethammer C, Czub S, Vincent A, Muller-Hermelink HK, et al. (2002) Expression of fetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain 125:1309-1319.
10. Gerbershagen MU, Wappler F, Fiege M, Kolodzie K, Weisshorn R, Szafarczyk W, Kudlik C, and Schulte Am Esch J (2003) Effects of a 5HT(2) receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia. Br J Anaesth 91:281-284.
11. Guiloff RJ and Modarres-Sadeghi H (1992) Voluntary activation and fiber density of fasciculations in motor neuron disease. Ann Neurol 31:416-424.
12. Hadad E, Cohen-Sivan Y, Heled Y, and Epstein Y (2005) Clinical review: treatment of heat stroke: should dantrolene be considered? Crit Care 9:86-91.
13. Hall AP, Lyburn ID, Spears FD, and Riley B (1996) An unusual case of Ecstasy poisoning. Intensive Care Med 22:670-671.
14. Henry JA, Jeffreys KJ, and Dawling S (1992) Toxicity and deaths from 3,4 methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387.
15. Henry JA (1992) Ecstasy and the dance of death. Br Med J 305:5-6.
16. Herrmann-Frank A, Lüttgau HC, and Stephenson DG (1999) Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. J Muscle Res Cell Mot 20:223-237.
17. Hoshi K, Hashimoto Y, and Matsukawa S (1993) Pharmacokinetics of succinylcholine in man. Tohoku J Exp Med 170:245-250.
18. Klingler W, Baur C, Georgieff M, Lehmann-Horn F, and Melzer W (2002) Detection of proton release from cultured human myotubes to identify malignant hyperthermia susceptibility. Anesthesiology 97:1059-1066.
19. Klingler W, Lehmann-Horn F, and Jurkat-Rott K (2005) Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15:195-206.
20. Koltgen D and Franke C (1992) Acetylcholine activates two types of ion channels in sarcolemma from adult muscular dystrophic (mdx) mice. Neurosci Lett 137:1-4.
21. Krampfl K, Jahn K, Cordes A, Dengler R, and Bufler J (2002) Analysis of a slow desensitized state of recombinant adult-type nicotinic acetylcholine receptor channels. Eur J Neurosci 16:652-658.
22. Lefebvre S, Burglen L, Frezal J, Munnich A, and Melki J (1998) The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet 7:1531-1536.
23. Lehmann-Horn F and Jurkat-Rott K (1999) Voltage-gated ion channels and hereditary disease. Physiol Rev 79:1317-1371.
24. Leonardi ET and Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238.
25. Liu PS, Liaw CT, Lin MK, Shin SH, Kao LS, and Lin LF (2003) Amphetamine enhances Ca2+ entry and catecholamine release via nicotinic receptor activation in bovine adrenal chromaffin cells. Eur J Pharmacol 460:9-17.
26. Lorenzon P, Bernareggi A, Degasperi V, Nurowska E, Wernig A, and Ruzzier F (2002) Properties of primary mouse myoblasts expanded in culture. Exp Cell Res 278:84-91.
27. Löwenick CV, Krampfl K, Schneck HJ, Kochs E, and Bufler J (2001) Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur J Pharmacol 413:31-35.
28. MacLennan DH and Phillips MS (1992) Malignant hyperthermia. Science (Wash DC) 256:789-794.
29. Martyn JA, White DA, Gronert GA, Jaffe RS, and Ward JM (1992) Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers. Anesthesiology 76:822-843.
30. Mechan AO, Esteban B, O'Shea, Elliot JM, Colado MI, and Green AR (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135:170-180.
31. Milroy CM, Clark JC, and Forrest ARW (1996) Pathology of deaths associated with 'ecstasy' and 'eve' misuse. J Clin Pathol 49:149-153.
32. Nimmo SM, Kennedy BW, Tullet WM, Blyth AS, and Dougall JR (1993) Drug-induced hyperthermia. Anaesthesia 48:892-895.
33. O'Connell D and Heffron JJA (2000) Rapid analysis of illicit drugs by mass spectrometry: results from seizures in Ireland. Analyst 125:119-121.
34. O'Leary G, Nargiso J, and Weiss RD (2001) 3,4- Methylenedioxymethamphetamine (MDMA): a review. Curr Psychiatry Rep 3:477-483.
35. Ørding H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJA, Heytens L, et al. (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesth Scand 41:955-966.
36. Ørding H and Skovgaard LT (1987) In-vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffein-suxamethonium. Acta Anaesth Scand 31:462-465.
37. O'Sullivan GH, McIntosh JM, and Heffron JJA (2001) Abnormal uptake and release of Ca2 ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol 61:1479-1485.
38. Rusyniak DE, Tandy SL, Hekmatyar SN, Mills E, Smith DJ, Bansal N, Maclellan D, Harper ME, and Sprague JE (2005) The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine mediated skeletal muscle hyperthermia and rhabdomyolysis. J Pharmacol Exp Ther 313:629-639.
39. Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, and Cohen SL (1992) Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339:677-678.
40. Skau KA and Gerald MC (1978) Inhibition of α-bungarotoxin binding to rat and mouse diaphragms by amphetamine and related nonquaternary compounds. J Pharmacol Exp Ther 205:69-76.